Genetic diversity in the collaborative cross model recapitulates human west nile virus disease outcomes

mBio

Volumn 6, Issue 3, 2015, Pages 1-11

  Graham, Jessica B ^a   Thomas, Sunil ^b   Swarts, Jessica ^a   McMillan, Aimee A ^b   Ferris, Martin T ^c   Suthar, Mehul S ^d   Treuting, Piper M ^e   Ireton, Renee ^b   Gale, Michael ^b   Lund, Jennifer M ^a,e  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; 2',5' OLIGOADENYLATE SYNTHETASE; OAS1B PROTEIN, MOUSE; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE SEQUENCE; GENETIC VARIABILITY; IFIT1 GENE; IFN BETA GENE; INFECTION SENSITIVITY; INNATE IMMUNITY; MALE; MEMORY CELL; MOUSE; NONHUMAN; OAS1B GENE; PRIORITY JOURNAL; SURVIVAL RATE; VIRAL CLEARANCE; VIRUS LOAD; VIRUS RESISTANCE; VIRUS TITRATION; WEST NILE FEVER; WEST NILE VIRUS; ANIMAL; BLOOD; CENTRAL NERVOUS SYSTEM; CROSS BREEDING; DISEASE MODEL; DISEASE PREDISPOSITION; DISEASE RESISTANCE; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; HUMAN; IMMUNOLOGY; INBRED MOUSE STRAIN; METABOLISM; PATHOGENICITY; PHENOTYPE; PHYSIOLOGY; VIROLOGY;

FLAVIVIRUS; MUS; WEST NILE VIRUS;

2',5'-OLIGOADENYLATE SYNTHETASE; ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, VIRAL; CENTRAL NERVOUS SYSTEM; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; DISEASE RESISTANCE; DISEASE SUSCEPTIBILITY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; IMMUNITY, INNATE; MICE; MICE, INBRED STRAINS; PHENOTYPE; VIRAL LOAD; WEST NILE FEVER; WEST NILE VIRUS;

EID: 84936936043     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00493-15     Document Type: Article

References (45)

1. Colpitts TM, Conway MJ, Montgomery RR, Fikrig E. 2012. West Nile virus: biology, transmission, and human infection. Clin Microbiol Rev 25:635-648. http://dx.doi.org/10.1128/CMR.00045-12.
2. Diamond MS, Mehlhop E, Oliphant T, Samuel MA. 2009. The host immunologic response to West Nile encephalitis virus. Front Biosci 14: 3024-3034. http://dx.doi.org/10.2741/3432.
3. Samuel MA, Diamond MS. 2006. Pathogenesis of West Nile virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol 80:9349-9360. http://dx.doi.org/10.1128/ JVI.01122-06.
4. Sejvar JJ. 2007. The long-term outcomes of human West Nile virus infection. Clin Infect Dis 44:1617-1624. http://dx.doi.org/10.1086/518281.
5. Sejvar JJ, Haddad MB, Tierney BC, Campbell GL, Marfin AA, Van Gerpen JA, Fleischauer A, Leis AA, Stokic DS, Petersen LR. 2003. Neurologic manifestations and outcome of West Nile virus infection. JAMA 290:511-515. http://dx.doi.org/10.1001/jama.290.4.511.
6. Lim JK, Louie CY, Glaser C, Jean C, Johnson B, Johnson H, McDermott DH, Murphy PM. 2008. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a metaanalysis of 4 cohorts in the US epidemic. J Infect Dis 197:262-265. http:// dx.doi.org/10.1086/524691.
7. Lim JK, McDermott DH, Lisco A, Foster GA, Krysztof D, Follmann D, Stramer SL, Murphy PM. 2010. CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J Infect Dis 201:178-185. http://dx.doi.org/10.1086/649426.
8. Loeb M, Eskandarian S, Rupp M, Fishman N, Gasink L, Patterson J, Bramson J, Hudson TJ, Lemire M. 2011. Genetic variants and susceptibility to neurological complications following West Nile virus infection. J Infect Dis 204:1031-1037. http://dx.doi.org/10.1093/infdis/jir493.
9. Carson PJ, Konewko P, Wold KS, Mariani P, Goli S, Bergloff P, Crosby RD. 2006. Long-term clinical and neuropsychological outcomes of West Nile virus infection. Clin Infect Dis 43:723-730. http://dx.doi.org/ 10.1086/506939.
10. Gottfried K, Quinn R, Jones T. 2005. Clinical description and follow-up investigation of human West Nile virus cases. South Med J 98:603-606. http://dx.doi.org/10.1097/01.SMJ.0000155633.43244.AC.
11. Klee AL, Maidin B, Edwin B, Poshni I, Mostashari F, Fine A, Layton M, Nash D. 2004. Long-term prognosis for clinical West Nile virus infection. Emerg Infect Dis 10:1405-1411. http://dx.doi.org/10.3201/ eid1008.030879.
12. Leis AA, Stokic DS, Webb RM, Slavinski SA, Fratkin J. 2003. Clinical spectrum of muscle weakness in human West Nile virus infection. Muscle Nerve 28:302-308. http://dx.doi.org/10.1002/mus.10440.
13. Marciniak C, Sorosky S, Hynes C. 2004. Acute flaccid paralysis associated with West Nile virus: motor and functional improvement in 4 patients. Arch Phys Med Rehabil 85:1933-1938. http://dx.doi.org/10.1016/ j.apmr.2004.04.038.
14. Wang H, Siddharthan V, Hall JO, Morrey JD. 2011. Autonomic nervous dysfunction in hamsters infected with West Nile virus. PLoS One 6:e19575. http://dx.doi.org/10.1371/journal.pone.0019575.
15. Lanteri MC, Heitman JW, Owen RE, Busch T, Gefter N, Kiely N, Kamel HT, Tobler LH, Busch MP, Norris PJ. 2008. Comprehensive analysis of West Nile virus-specific T cell responses in humans. J Infect Dis 197: 1296-1306. http://dx.doi.org/10.1086/586898.
16. Lanteri MC, O'Brien KM, Purtha WE, Cameron MJ, Lund JM, Owen RE, Heitman JW, Custer B, Hirschkorn DF, Tobler LH, Kiely N, Prince HE, Ndhlovu LC, Nixon DF, Kamel HT, Kelvin DJ, Busch MP, Rudensky AY, Diamond MS, Norris PJ. 2009. Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest 119:3266-3277. http://dx.doi.org/10.1172/JCI39387.
17. Petersen LR, Fischer M. 2012. Unpredictable and difficult to control-the adolescence of West Nile virus. N Engl J Med 367:1281-1284. http:// dx.doi.org/10.1056/NEJMp1210537.
18. Daffis S, Samuel MA, Keller BC, Gale M, Jr, Diamond MS. 2007. Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and-independent mechanisms. PLoS Pathog 3:e106. http://dx.doi.org/10.1371/journal.ppat.0030106.
19. Daffis S, Samuel MA, Suthar MS, Gale M, Jr, Diamond MS. 2008. Toll-like receptor 3 has a protective role against West Nile virus infection. J Virol 82:10349-10358. http://dx.doi.org/10.1128/JVI.00935-08.
20. Daffis S, Samuel MA, Suthar MS, Keller BC, Gale M, Jr, Diamond MS. 2008. Interferon regulatory factor IRF-7 induces the antiviral alpha interferon response and protects against lethal west Nile virus infection. J Virol 82:8465-8475. http://dx.doi.org/10.1128/JVI.00918-08.
21. Samuel MA, Whitby K, Keller BC, Marri A, Barchet W, Williams BR, Silverman RH, Gale M, Jr, Diamond MS. 2006. PKR and RNase L contribute to protection against lethal West Nile virus infection by controlling early viral spread in the periphery and replication in neurons. J Virol 80:7009-7019. http://dx.doi.org/10.1128/JVI.00489-06.
22. Suthar MS, Ma DY, Thomas S, Lund JM, Zhang N, Daffis S, Rudensky AY, Bevan MJ, Clark EA, Kaja MK, Diamond MS, Gale M, Jr. 2010. IPS-1 is essential for the control of West Nile virus infection and immunity. PLoS Pathog 6:e1000757. http://dx.doi.org/10.1371/ journal.ppat.1000757.
23. Kawai T, Akira S. 2007. Antiviral signaling through pattern recognition receptors. J Biochem 141:137-145. http://dx.doi.org/10.1093/jb/ mvm032.
24. Suthar MS, Diamond MS, Gale M, Jr. 2013. West Nile virus infection and immunity. Nat Rev Microbiol 11:115-128. http://dx.doi.org/10.1038/ nrmicro2950.
25. Keller BC, Fredericksen BL, Samuel MA, Mock RE, Mason PW, Diamond MS, Gale M, Jr. 2006. Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J Virol 80:9424-9434. http://dx.doi.org/10.1128/JVI.00768-06.
26. Suthar MS, Ma DY, Thomas S, Lund JM, Zhang N, Daffis S, Rudensky AY, Bevan MJ, Clark EA, Kaja MK, Diamond MS, Gale M, Jr. 2010. IPS-1 is essential for the control of West Nile virus infection and immunity. PLoS Pathog 6:e1000757. http://dx.doi.org/10.1371/ journal.ppat.1000757.
27. Errett JS, Suthar MS, McMillan A, Diamond MS, Gale M, Jr. 2013. The essential, nonredundant roles of RIG-I and MDA5 in detecting and controlling West Nile virus infection. J Virol 87:11416-11425. http:// dx.doi.org/10.1128/JVI.01488-13.
28. Diamond MS, Shrestha B, Marri A, Mahan D, EngleM. 2003. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 77:2578-2586. http:// dx.doi.org/10.1128/JVI.77.4.2578-2586.2003.
29. Diamond MS, Sitati EM, Friend LD, Higgs S, Shrestha B, Engle M. 2003. A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med 198:1853-1862. http://dx.doi.org/10.1084/ jem.20031223.
30. Wang Y, Lobigs M, Lee E, Koskinen A, Müllbacher A. 2006. CD8(+) T cell-mediated immune responses in West Nile virus (Sarafend strain) encephalitis are independent of gamma interferon. J Gen Virol 87: 3599-3609. http://dx.doi.org/10.1099/vir.0.81306-0.
31. Churchill GA, Airey DC, Allayee H, Angel JM, Attie AD, Beatty J, Beavis WD, Belknap JK, Bennett B, Berrettini W, Bleich A, Bogue M, Broman KW, Buck KJ, Buckler E, Burmeister M, Chesler EJ, Cheverud JM, Clapcote S, Cook MN, Cox RD, Crabbe JC, Crusio WE, Darvasi A, Deschepper CF, Doerge RW, Farber CR, Forejt J, Gaile D, Garlow SJ, Geiger H, Gershenfeld H, Gordon T, Gu J, Gu W, de Haan G, Hayes NL, Heller C, Himmelbauer H, Hitzemann R, Hunter K, Hsu HC. 2004. The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet 36:1133-1137. http://dx.doi.org/10.1038/ ng1104-1133.
32. Threadgill DW, Churchill GA. 2012. Ten years of the Collaborative Cross. G3 2:153-156. http://dx.doi.org/10.1534/g3.111.001891.
33. Threadgill DW, Miller DR, Churchill GA, de Villena FP. 2011. The Collaborative Cross: a recombinant inbred mouse population for the systems genetic era. ILAR J 52:24-31. http://dx.doi.org/10.1093/ilar.52.1.24.
34. Roberts A, Pardo-Manuel de Villena F, Wang W, McMillan L, Threadgill DW. 2007. The polymorphism architecture of mouse genetic resources elucidated using genome-wide resequencing data: implications for QTL discovery and systems genetics. Mamm Genome 18:473-481. http://dx.doi.org/10.1007/s00335-007-9045-1.
35. Grandvaux N, Servant MJ, tenOever B, Sen GC, Balachandran S, Barber GN, Lin R, Hiscott J. 2002. Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. J Virol 76:5532-5539. http://dx.doi.org/ 10.1128/JVI.76.11.5532-5539.2002.
36. Courtney SC, Di H, Stockman BM, Liu H, Scherbik SV, Brinton MA. 2012. Identification of novel host cell binding partners of Oas1b, the protein conferring resistance to flavivirus-induced disease in mice. J Virol 86:7953-7963. http://dx.doi.org/10.1128/JVI.00333-12.
37. Simon-Chazottes D, Frenkiel MP, Montagutelli X, Guénet JL, Desprès P, Panthier JJ. 2011. Transgenic expression of full-length 2=,5=-oligoadenylate synthetase 1b confers to BALB/c mice resistance against West Nile virus-induced encephalitis. Virology 417:147-153. http:// dx.doi.org/10.1016/j.virol.2011.05.018.
38. Keane TM, Goodstadt L, Danecek P, White MA, Wong K, Yalcin B, Heger A, Agam A, Slater G, Goodson M, Furlotte NA, Eskin E, Nellåker C, Whitley H, Cleak J, Janowitz D, Hernandez-Pliego P, Edwards A, Belgard TG, Oliver PL, McIntyre RE, Bhomra A, Nicod J, Gan X, Yuan W, van der Weyden L, Steward CA, Bala S, Stalker J, Mott R, Durbin R, Jackson IJ, Czechanski A, Guerra-Assuncao JA, Donahue LR, Reinholdt LG, Payseur BA, Ponting CP, Birney E, Flint J, Adams DJ. 2011. Mouse genomic variation and its effect on phenotypes and gene regulation. Nature 477:289-294. http://dx.doi.org/10.1038/nature10413.
39. Imran M, Manzoor S, Khattak NM, Tariq M, Khalid M, Javed F, Bhatti S. 2014. Correlation of OAS1 gene polymorphism at exon 7 splice accepter site with interferon-based therapy of HCV infection in Pakistan. Viral Immunol 27:105-111. http://dx.doi.org/10.1089/vim.2013.0107.
40. Urosevic N, Silvia OJ, Sangster MY, Mansfield JP, Hodgetts SI, Shellam GR. 1999. Development and characterization of new flavivirus-resistant mouse strains bearing Flv(r)-like and Flv(mr) alleles from wild or wildderived mice. J Gen Virol 80:897-906.
41. Bigham AW, Buckingham KJ, Husain S, Emond MJ, Bofferding KM, Gildersleeve H, Rutherford A, Astakhova NM, Perelygin AA, Busch MP, Murray KO, Sejvar JJ, Green S, Kriesel J, Brinton MA, Bamshad M. 2011. Host genetic risk factors for West Nile virus infection and disease progression. PLoS One 6:e24745. http://dx.doi.org/10.1371/ journal.pone.0024745.
42. Thamizhmani R, Vijayachari P. 2014. Association of dengue virus infection susceptibility with polymorphisms of 2=-5=-oligoadenylate synthetase genes: a case-control study. Braz J Infect Dis 18:548-550. http:// dx.doi.org/10.1016/j.bjid.2014.03.004.
43. Ferris MT, Aylor DL, Bottomly D, Whitmore AC, Aicher LD, Bell TA, Bradel-Tretheway B, Bryan JT, Buus RJ, Gralinski LE, Haagmans BL, McMillan L, Miller DR, Rosenzweig E, Valdar W, Wang J, Churchill GA, Threadgill DW, McWeeney SK, Katze MG, de Villena P-M F, Baric RS, HeiseMT. 2013. Modeling host genetic regulation of influenza pathogenesis in the collaborative cross. PLOS Pathog 9:e1003196. http:// dx.doi.org/10.1371/journal.ppat.1003196.
44. Zou S, Foster GA, Dodd RY, Petersen LR, Stramer SL. 2010. West Nile fever characteristics among viremic persons identified through blood donor screening. J Infect Dis 202:1354-1361. http://dx.doi.org/10.1086/ 656602.
45. Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, Campbell GL. 2005. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis 11:1174-1179. http://dx.doi.org/10.3201/ eid1108.050289b.